logo
Share SHARE
FONT-SIZE Plus   Neg

Genentech's Perjeta Regimen Gets Priority Review For HER2-Positive Breast Cancer

Genentech, a member of the Roche Group (RHHBY.PK), reported that the U.S. Food and Drug Administration or FDA has accepted the company's supplemental Biologics License Application or sBLA for the use of a Perjeta regimen before surgery in people with HER2-positive early stage breast cancer. The FDA has granted a Priority Review of the application and would decide on approval by October 31, 2013.

Neoadjuvant therapy, a treatment option given after diagnosis but before surgery for early stage breast cancer, aims to reduce a tumor's size so it may be easier to surgically remove, or to allow for breast-conserving surgery. Perjeta is a personalized medicine that targets the HER2 receptor, a protein found in high quantities on the outside of cancer cells in HER2-positive cancers. The combination of Perjeta, Herceptin and docetaxel chemotherapy is thought to provide a more comprehensive blockade of HER signaling pathways, Genentech added.

A priority review designation is awarded to medicines that the FDA hopes to have the potential to provide significant improvements in the treatment, prevention or diagnosis of a disease. The application is based mainly on results from NEOSPHERE and TRYPHAENA, two Phase II studies of Perjeta in HER2-positive early stage breast cancer, and on longer-term safety data from the Phase III CLEOPATRA trial of Perjeta in HER2-positive metastatic breast cancer.

The TRYPHAENA study is a randomized, multicenter Phase II trial that was conducted in 225 people with HER2-positive, locally advanced, inflammatory or early stage breast cancer.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Gatorade Co. agreed to pay $300,000 to settle a complaint with California over a mobile game that discouraged drinking water, the California attorney general's office said last week. The settlement terms also call for putting $120,000 toward the study or promotion of childhood and teenage nutrition and consumption of water. Consumer goods giant Unilever plc Monday said it has agreed to acquire Carver Korea, a Seoul-based maker of toners and moisturizers, for 2.27 billion euros from Bain Capital Private Equity and Goldman Sachs. The company expects the acquisition to help it to gain ground in the Korean beauty market, said to be the fourth largest skincare market in the world. Swiss engineering firm ABB Ltd. announced Monday its agreement to acquire GE Industrial Solutions, the electrification solutions business of Conglomerate General Electric Co., for $2.6 billion. The acquisition includes a long-term right to use the GE brand. ABB expects the acquisition to strengthen its Number 2 position in electrification globally and expand access to North America.
comments powered by Disqus
Follow RTT